Roche Holding AG
RHHBF
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
E: investor.relations@roche.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
markets
Morningstar runs the numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended 10 January.
stocks
7 defensive stocks on sale
Equities have been in rally mode for most of the past decade and it's not unreasonable to suggest that playing a little defence right now might be a good idea.
stocks
Finding recession-proof companies
Morningstar's Peter Bull likes companies with pricing power and niche products, and names that catch his eye include Microsoft, Colgate and luxury retailers like Louis Vuitton and Christian Dior.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,847.60 | 205.10 | -2.55% |
| CAC 40 | 7,258.37 | 340.61 | -4.48% |
| DAX 40 | 20,594.60 | 1,122.79 | -5.17% |
| Dow JONES (US) | 39,128.99 | 1,416.94 | -3.49% |
| FTSE 100 | 8,066.39 | 408.35 | -4.82% |
| HKSE | 22,849.81 | 352.72 | -1.52% |
| NASDAQ | 15,804.70 | 745.90 | -4.51% |
| Nikkei 225 | 33,780.58 | 955.35 | -2.75% |
| NZX 50 Index | 12,225.28 | 113.29 | -0.92% |
| S&P 500 | 5,173.83 | 222.69 | -4.13% |
| S&P/ASX 200 | 7,667.80 | 191.90 | -2.44% |
| SSE Composite Index | 3,342.01 | 8.12 | -0.24% |